Dapagliflozin
http://www.google.co.in/patents/US6515117
HPLC retention time: 7.08 min, 94% pure, YMC S5 C-18 4.6×50 mm column, 2.5 mL/min, detection at 220 nM; 8 min gradient 0-100% B hold 5 min at 100% B. Solvent A: 10% MeOH/H2O+0.2% H3PO4. Solvent B: 90% MeOH/H2O+0.2% H3PO4.
1H NMP (500 MHz, CD3OD) δ7.33 (d, 1H, J=6 Hz), 7.31 (d, 1H, J=2.2 Hz), 7.31 (dd, 1H, J=6 Hz, J=2.2 Hz), 7.07 (d, 2H, J=8.8 Hz), 6.78 (d, 2H, J=8.8 Hz), 4.07-3.90 (m, 7H), 3.85 (d, 1H, J=10.6 Hz), 3.69 (dd, 1H, J=5.3, 10.6 Hz), 3.42-3.25 (m, 4H) Hz), 1.34 (t, 3H, J=7 Hz).
13C NMP (125 MHz, CD3OD) δ158.8, 140.0, 139.9, 134.4, 132.9, 131.9, 130.8, 130.1, 128.2, 115.5, 82.9, 82.2, 79.7, 76.4, 71.9, 64.5, 63.1, 39.2, 15.2.
Anal Calcd for C21H25ClO6 LC-MS [M+Na+]431; found 431.
 | |
| Systematic (IUPAC) name | |
|---|---|
| (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol | |
| Clinical data | |
| Trade names | Forxiga, Farxiga |
| AHFS/Drugs.com | UK Drug Information |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. |
|
| Legal status | |
| Routes | Oral |
| Identifiers | |
| CAS number | 461432-26-8  |
| ATC code | A10BX09 |
| PubChem | CID 9887712 |
| ChemSpider | 8063384  |
| UNII | 1ULL0QJ8UC |
| ChEMBL | CHEMBL429910 |
| Synonyms | BMS-512148 |
| Chemical data | |
| Formula | C21H25ClO6 |
| Mol. mass | 408.873 g/mol |
| Citing Patent | Filing date | Publication date | Applicant | Title |
|---|---|---|---|---|
| US6774112 * | 8 Apr 2002 | 10 Aug 2004 | Bristol-Myers Squibb Company | Antidiabetic agents; cardiovascular disorders |
| US6936590 * | 4 Oct 2002 | 30 Aug 2005 | Bristol Myers Squibb Company | Treating diabetic with a sodium dependent glucose transporters (SGLT2) inhibitors, especially type II diabetes; use of pyran compounds including dapaglifozin |
| US7084124 | 30 Jul 2004 | 1 Aug 2006 | Janssen Pharmaceutica, N.V. | Antidiabetic agents; insulin resistance |
| US7094763 * | 30 Jul 2004 | 22 Aug 2006 | Janssen Pharaceutica, N.V. | e.g., 2-(4-Ethylbenzyl)-4-( beta -D-glucopyranosyl)-1H-indole, used for the treatment or prophylaxis of diabetes and Syndrome X. |
| US7094764 | 30 Jul 2004 | 22 Aug 2006 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides |
| US7129220 | 30 Jul 2004 | 31 Oct 2006 | Janssen Pharmaceutica N.V | Substituted indole-O-glucosides |
| US7169761 * | 4 Aug 2003 | 30 Jan 2007 | Astellas Pharma Inc. | Azulene derivatives and salts thereof |
| US7199159 * | 23 May 2001 | 3 Apr 2007 | Centre National De La Recherche Scientifique (C.N.R.S.) | Use of biguanide derivatives for making a medicine having a wound healing effect |
| US7238702 | 9 Feb 2006 | 3 Jul 2007 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
| US7288528 * | 12 Dec 2003 | 30 Oct 2007 | Sanofi-Aventis Deutschland Gmbh | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof |
| US7371759 | 21 Sep 2004 | 13 May 2008 | Bristol-Myers Squibb Company | Anticholesterol agents; reducing blood serum lipids; anticancer agents; antiarthritic agents; antiinflammatory agents; antitumor agents; immunosuppressants; obesity; hypotensive agents |
| US7375213 | 23 Dec 2003 | 20 May 2008 | Bristol-Myers Squibb Company | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin |
| US7417032 | 27 Jul 2005 | 26 Aug 2008 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture |
| US7420059 | 15 Nov 2004 | 2 Sep 2008 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US7482330 | 15 Jun 2006 | 27 Jan 2009 | Janssen Pharmaceutica N.V. | 3-(4-Ethylbenzyl)-5-( beta -D-glucopyranosyl)-1H-indole; antidiabetic agents; insulin resistance |
| US7511020 | 15 Jun 2006 | 31 Mar 2009 | Janssen Pharmaceutica N.V. | 2-[3-(4-Ethyl-benzyl)-3H-benzoimidazol-4-yloxy]- .squ. -D-glucoglucopyranoside; sodium glucose transporter inhibitor; antidiabetic agent; Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, and cataracts |
| US7511021 | 2 Jun 2006 | 31 Mar 2009 | Janssen Pharmaceutica N.V. | 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-6-methyl-1H-indazol-4-yloxy} beta-D-glucopyranoside; sodium glucose transporter inhibitor; antidiabetic agent; Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, ischemia, stroke, heart disease , and cataracts |
| US7511022 | 15 Jun 2006 | 31 Mar 2009 | Janssen Pharmaceutica N.V. | Substituted indole-O-glucosides |
| US7566699 | 24 Mar 2004 | 28 Jul 2009 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| US7576063 | 30 Sep 2003 | 18 Aug 2009 | Kissei Pharmaceutical Co., Ltd. | prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole |
| US7579449 | 15 Mar 2005 | 25 Aug 2009 | Boehringer Ingelheim International Gmbh | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene |
| US7662790 | 13 Apr 2006 | 16 Feb 2010 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| US7666845 | 3 Dec 2007 | 23 Feb 2010 | Janssen Pharmaceutica N.V. | Compounds having inhibitory activity against sodium-dependent glucose transporter |
| US7683160 | 29 Aug 2006 | 23 Mar 2010 | Boehringer Ingelheim International Gmbh | 1-chloro-4-( beta -D-glucopyranos-1-yl)-2-[4-((1R,2R)-2-hydroxy-cyclopent-1-yloxy)-benzyl]-benzene; metabolic disorders such as diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia; sodium-dependent glucose cotransporter SGLT2 inhibitors |
| US7687469 | 15 Dec 2005 | 30 Mar 2010 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| US7713938 | 19 Apr 2006 | 11 May 2010 | Boehringer Ingelheim International Gmbh | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7723309 | 21 Apr 2006 | 25 May 2010 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7745414 | 14 Feb 2007 | 29 Jun 2010 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| US7772191 | 3 May 2006 | 10 Aug 2010 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| US7772378 | 22 Feb 2006 | 10 Aug 2010 | Boehringer Ingelheim International Gmbh | inhibiting sodium-dependent glucose cotransporter SGLT2; diabetes mellitus, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias, atherosclerosis, obesity, high blood pressure, chronic heart failure |
| US7776830 | 1 May 2007 | 17 Aug 2010 | Boehringer Ingelheim International Gmbh | sodium-dependent glucose cotransporter (SGLT2) inhibitor; improved pharmacological or pharmacokinetic properties; antidiabetic agent, metabolic disorders, obesity, insulin resistance, atherosclerosis, chronic heart failure, liver fat |
| US7781577 | 27 Sep 2007 | 24 Aug 2010 | Lexicon Pharmaceuticals, Inc. | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents |
| US7795436 | 24 Aug 2006 | 14 Sep 2010 | Bristol-Myers Squibb Company | cis-6-(2,4-Dichloro-phenyl)-1,2,3,4,4a,9a-hexahydro-3-aza-fluoren-9-one, used for treating metabolic disorders, nervous system disorders, headaches, gastrointestinal disorders and as analgesics |
| US7816328 | 11 Sep 2009 | 19 Oct 2010 | Janssen Pharmaceutica Nv | such as 3-(4-Ethylbenzyl)-5-( beta -D-glucopyranosyl)-1H-indole, used for for treating diabetes, Syndrome X, or associated symptoms selected from obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke and cardiovascula disorders |
| US7816330 | 11 Sep 2009 | 19 Oct 2010 | Janssen Pharmaceutica Nv | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
| US7816331 | 22 Sep 2009 | 19 Oct 2010 | Janssen Pharmaceutica Nv | Substituted indazole-O-glucosides |
| US7820630 | 22 Sep 2009 | 26 Oct 2010 | Janssen Pharmaceutica Nv | Substituted indole-O-glucosides |
| US7838499 | 22 Aug 2008 | 23 Nov 2010 | Theracos, Inc. | (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-(2-methoxyethoxy)ethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; for treating diseases assoicated with sodium glucose co-transporter inhibition (SGLT) such as diabetes, hyperglycemia, insulin resistance, metabolic syndrome, atherosclerosis |
| US7846945 | 4 Mar 2008 | 7 Dec 2010 | Lexicon Pharmaceuticals, Inc. | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents |
| US7847074 | 14 Sep 2006 | 7 Dec 2010 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof |
| US7851502 * | 21 Mar 2008 | 14 Dec 2010 | Bristol-Myers Squibb Company | Pharmaceutical formulations containing an SGLT2 inhibitor |
| US7851602 | 27 Jul 2006 | 14 Dec 2010 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| US7851617 | 26 Jul 2007 | 14 Dec 2010 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
| US7888487 | 3 Aug 2009 | 15 Feb 2011 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| US7919598 * | 20 Jun 2007 | 5 Apr 2011 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| US7932379 | 19 Jun 2007 | 26 Apr 2011 | Bristol-Myers Squibb Company | Methods of producing C-aryl glucoside SGLT2 inhibitors |
| US7935674 | 18 Jun 2009 | 3 May 2011 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
| US7943582 | 3 Dec 2007 | 17 May 2011 | Mitsubishi Tanabe Pharma Corporation | Canagliflozin, a sodium-glucose transporter 2 inhibitor as antiobesity, antidiabetic agent; purity; handling characteristics; easy formulation; storage stability |
| US7943656 | 18 Apr 2008 | 17 May 2011 | Bristol-Myers Squibb Company | Crystal forms of saxagliptin and processes for preparing same |
| US7943788 | 31 Jan 2005 | 17 May 2011 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| US8026347 | 17 Jul 2008 | 27 Sep 2011 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
| US8080580 | 24 Aug 2009 | 20 Dec 2011 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| US8088743 * | 21 Mar 2008 | 3 Jan 2012 | Bristol-Myers Squibb Company | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside |
| US8106021 | 1 Nov 2010 | 31 Jan 2012 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
| US8129434 | 11 Dec 2008 | 6 Mar 2012 | Theracos, Inc. | Benzylphenyl cyclohexane derivatives and methods of use |
| US8198464 | 20 Dec 2007 | 12 Jun 2012 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
| US8202984 | 13 Jan 2011 | 19 Jun 2012 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| US8221786 | 18 Nov 2010 | 17 Jul 2012 | Bristol-Myers Squibb Company | Pharmaceutical formulations containing an SGLT2 inhibitor |
| US8222219 | 1 Jul 2011 | 17 Jul 2012 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| US8236847 | 6 Apr 2011 | 7 Aug 2012 | Bristol-Myers Squibb Company | Crystal forms of saxagliptin and processes for preparing same |
| US8278268 | 24 Oct 2007 | 2 Oct 2012 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| US8283454 | 21 Aug 2009 | 9 Oct 2012 | Theracos, Inc. | Processes for the preparation of SGLT2 inhibitors |
| US8293878 | 11 Aug 2011 | 23 Oct 2012 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
| US8361972 | 21 Jun 2012 | 29 Jan 2013 | Bristol Myers-Squibb Company | Pharmaceutical formulations containing an SGLT2 inhibitor |
| US8476413 | 18 Aug 2010 | 2 Jul 2013 | Lexicon Pharmaceuticals, Inc. | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
| US8501698 | 16 Mar 2011 | 6 Aug 2013 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| US8507450 | 7 Sep 2006 | 13 Aug 2013 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| US8513202 | 9 May 2011 | 20 Aug 2013 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
| US8551957 | 15 Aug 2008 | 8 Oct 2013 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
| US8557782 | 9 Jun 2010 | 15 Oct 2013 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| US8575321 | 21 Dec 2011 | 5 Nov 2013 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
| US8603989 * | 15 May 2009 | 10 Dec 2013 | Bristol-Myers Squibb Company | Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same |
| US8652527 | 19 Mar 2013 | 18 Feb 2014 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US8669380 | 21 Oct 2010 | 11 Mar 2014 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| US8685934 * | 26 May 2010 | 1 Apr 2014 | Bristol-Myers Squibb Company | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
| US8716251 | 4 Jan 2013 | 6 May 2014 | Bristol-Myers Squibb Company | Pharmaceutical formulations containing an SGLT2 inhibitor |
| US8772512 | 8 Jul 2010 | 8 Jul 2014 | Janssen Pharmaceutica Nv | Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene |
| US8785403 | 12 Jun 2012 | 22 Jul 2014 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| US8791077 * | 15 May 2009 | 29 Jul 2014 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| US8802637 | 30 Sep 2013 | 12 Aug 2014 | Theracos, Inc. | Benzylbenzene derivatives and methods of use |
| US8802715 | 27 Dec 2013 | 12 Aug 2014 | Astrazeneca Ab | Crystal forms of saxagliptin and processes for preparing same |
| US8802842 | 28 Sep 2010 | 12 Aug 2014 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form |
| US20110003757 * | 29 Jan 2009 | 6 Jan 2011 | Astellas Pharma Inc. | Pharmaceutical compositions for treating fatty liver disease |
| US20110065658 * | 15 May 2009 | 17 Mar 2011 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
| US20110077213 * | 15 May 2009 | 31 Mar 2011 | Bristol-Myers Squibb Company | Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same |
| US20110098240 * | 15 Aug 2008 | 28 Apr 2011 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor |
| US20120041069 * | 18 Apr 2011 | 16 Feb 2012 | Nectid Inc. | Sglt2 inhibitor dosage forms |
| US20120071403 * | 26 May 2010 | 22 Mar 2012 | Astrazeneca Uk Limited | Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof |
| US20120077739 * | 2 Dec 2011 | 29 Mar 2012 | Bristol-Myers Squibb | Methods for treating obesity employing an sglt2 inhibitor and compositions thereof |
| US20130023486 * | 14 Jan 2011 | 24 Jan 2013 | Tianjin Institute Of Pharmaceutical Research | Phenyl c-glucoside derivatives, preparation methods and uses thereof |
| CN102167715B | 7 Mar 2011 | 24 Apr 2013 | 上海惠斯生物科技有限公司 | Eutectic preparation method of sodium-glucose cotransporter 2 bulk pharmaceutical chemicals |
| EP2308841A2 | 27 Sep 2007 | 13 Apr 2011 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as SGLT2 inhibitors |
| EP2455374A1 | 15 Oct 2009 | 23 May 2012 | Janssen Pharmaceutica N.V. | Process for the Preparation of Compounds useful as inhibitors of SGLT |
| EP2457908A1 | 15 Oct 2009 | 30 May 2012 | Janssen Pharmaceutica N.V. | Process for the Preparation of Compounds useful as inhibitors of SGLT |
| EP2457918A2 | 21 Jun 2007 | 30 May 2012 | Bristol-Myers Squibb Company | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes |
| EP2481726A2 | 18 Apr 2008 | 1 Aug 2012 | Bristol-Myers Squibb Company | Crystal forms of saxagliptin and processes for preparing same |
| EP2514756A1 | 30 Jul 2004 | 24 Oct 2012 | Mitsubishi Tanabe Pharma Corporation | Novel compounds having inhibitory activity against sodium-dependant glucose transporter |
| EP2668953A1 | 15 May 2009 | 4 Dec 2013 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis |
| WO2003099836A1 * | 15 May 2003 | 4 Dec 2003 | Squibb Bristol Myers Co | C-aryl glucoside sglt2 inhibitors and method |
| WO2004080990A1 | 12 Mar 2004 | 23 Sep 2004 | Kazuhiro Ikegai | C-glycoside derivatives and salts thereof |
| WO2005012318A2 * | 30 Jul 2004 | 10 Feb 2005 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
| WO2006019886A2 | 14 Jul 2005 | 23 Feb 2006 | Saleem Ahmad | Pyrrolo(oxo)isoquinolines as 5ht ligands |
| WO2008006043A2 | 6 Jul 2007 | 10 Jan 2008 | Squibb Bristol Myers Co | 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents |
| WO2008042688A2 | 27 Sep 2007 | 10 Apr 2008 | Lexicon Pharmaceuticals Inc | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| WO2009035969A1 * | 9 Sep 2008 | 19 Mar 2009 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt |
| WO2011051864A1 | 21 Oct 2010 | 5 May 2011 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2011060256A2 | 12 Nov 2010 | 19 May 2011 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
| WO2011060290A2 | 12 Nov 2010 | 19 May 2011 | Bristol-Myer Squibb Company | Immediate release tablet formulations |
| WO2011070592A2 | 9 Dec 2010 | 16 Jun 2011 | Panacea Biotec Ltd. | Novel sugar derivatives |
| WO2011142478A1 | 11 May 2011 | 17 Nov 2011 | Mitsubishi Tanabe Pharma Corporation | Canagliflozin containing tablets |
| WO2012031124A2 | 1 Sep 2011 | 8 Mar 2012 | Astrazeneca Uk Limited | Drug formulations using water soluble antioxidants |
| WO2012106303A1 | 31 Jan 2012 | 9 Aug 2012 | Astrazeneca Uk Limited | Pharmaceutical formulations including an amine compound |
